Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFBX in a rat heart failure model

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Palus, Sandra ^a   Schur, Robert ^b   Akashi, Yoshihiro J ^a   Bockmeyer, Barbara ^a   Datta, Rakesh ^c   Halem, Heather ^c   Dong, Jesse ^c   Culler, Michael D ^c   Adams, Volker ^b   Anker, Stefan D ^a,d   Springer, Jochen ^a,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c IPSEN   (France)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATROGIN 1; BIM 28125; BIM 28131; FUROSEMIDE; GHRELIN; MUSCLE RING FINGER 1 PROTEIN; PLACEBO; UNCLASSIFIED DRUG; BIM-28125; DRUG DERIVATIVE; FBXO32 PROTEIN, RAT; MUSCLE PROTEIN; TRIM63 PROTEIN, RAT; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CARDIAC CACHEXIA; CONTROLLED STUDY; DRUG MECHANISM; ECHOCARDIOGRAPHY; FOOD INTAKE; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; MALE; NONHUMAN; OSMOTIC PUMP; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; WEIGHT GAIN; ANIMAL; DISEASE MODEL; DRUG EFFECT; HEMODYNAMICS; HUMAN; METABOLISM; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION; WESTERN BLOTTING;

ANIMALIA; RATTUS;

ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; GHRELIN; HEART FAILURE; HEMODYNAMICS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MUSCLE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SKP CULLIN F-BOX PROTEIN LIGASES; UBIQUITIN-PROTEIN LIGASES; WEIGHT GAIN;

EID: 81055144834     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026865     Document Type: Article

References (32)

1. Krum H, Haas SJ, Eichhorn E, Ghali J, Gilbert E, et al. (2005) Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors. Eur Heart J 26: 2154-2158 Epub 2005 Jul 2113.
2. Bertrand ME, (2004) Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 20: 1559-1569.
3. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, et al. (1997) Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349: 1050-1053.
4. Anker SvHaSD, (2010) Cachexia as a major underestimated and unmet medical need: facts and numbers. Journal of Cachexia, Sarcopenia and Muscle 1: 1-5.
5. Springer J, Filippatos G, Akashi YJ, Anker SD, (2006) Prognosis and therapy approaches of cardiac cachexia. Curr Opin Cardiol 21: 229-233.
6. Anker SD, Volterrani M, Pflaum CD, Strasburger CJ, Osterziel KJ, et al. (2001) Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 38: 443-452.
7. Cicoira M, Kalra PR, Anker SD, (2003) Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail 9: 219-226.
8. Schulze PC, Gielen S, Adams V, Linke A, Mobius-Winkler S, et al. (2003) Muscular levels of proinflammatory cytokines correlate with a reduced expression of insulinlike growth factor-I in chronic heart failure. Basic Res Cardiol 98: 267-274.
9. Attaix D, Combaret L, Pouch MN, Taillandier D, (2001) Regulation of proteolysis. Curr Opin Clin Nutr Metab Care 4: 45-49.
10. Hasselgren PO, Fischer JE, (2001) Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann Surg 233: 9-17.
11. Cao PR, Kim HJ, Lecker SH, (2005) Ubiquitin-protein ligases in muscle wasting. Int J Biochem Cell Biol 37: 2088-2097 Epub 2004 Dec 2014.
12. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, et al. (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708 Epub 2001 Oct 1725.
13. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, et al. (2001) A role for ghrelin in the central regulation of feeding. Nature 409: 194-198.
14. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, et al. (2001) Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 104: 1430-1435.
15. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, et al. (2004) Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110: 3674-3679.
16. Adams V, Linke A, Wisloff U, Doring C, Erbs S, et al. (2007) Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: Effect on myocardial contractility. Cardiovasc Res 73: 120-129 Epub 2006 Nov 2001.
17. Dimmeler S, Assmus B, Hermann C, Haendeler J, Zeiher AM, (1998) Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circ Res 83: 334-341.
18. Müller DP-T TimoD, Tong Jenny, Pfluger PaulT, Tschöp MatthiasH, (2010) Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia. Journal of Cachexia, Sarcopenia and Muscle 1: 159-167.
19. Toshinai K, Yamaguchi H, Sun Y, Smith RG, Yamanaka A, et al. (2006) Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor. Endocrinology 147: 2306-2314 Epub 2006 Feb 2316.
20. Akashi YJ, Palus S, Datta R, Halem H, Taylor JE, et al. (2009) No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure. Int J Cardiol 137: 267-275 Epub 2008 Aug 2023.
21. Klok MD, Jakobsdottir S, Drent ML, (2007) The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 8: 21-34.
22. Balasubramaniam A, Wood S, Joshi R, Su C, Friend LA, et al. (2006) Ghrelin stimulates food intake and growth hormone release in rats with thermal injury: synthesis of ghrelin. Peptides 27: 1624-1631 Epub 2006 Mar 1630.
23. Tschop M, Smiley DL, Heiman ML, (2000) Ghrelin induces adiposity in rodents. Nature 407: 908-913.
24. Nogueiras R, Perez-Tilve D, Wortley KE, Tschop M, (2006) Growth hormone secretagogue (ghrelin-) receptors-a complex drug target for the regulation of body weight. CNS Neurol Disord Drug Targets 5: 335-343.
25. Sheriff S, Joshi R, Friend LA, James JH, Balasubramaniam A, (2009) Ghrelin receptor agonist, GHRP-2, attenuates burn injury-induced MuRF-1 and MAFbx expression and muscle proteolysis in rats. Peptides 30: 1909-1913 Epub 2009 Jul 1903.
26. Kalantar-Zadeh K, Kuwae N, Wu DY, Shantouf RS, Fouque D, et al. (2006) Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr 83: 202-210.
27. Davos CH, Doehner W, Rauchhaus M, Cicoira M, Francis DP, et al. (2003) Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail 9: 29-35.
28. Lavie CJ, Osman AF, Milani RV, Mehra MR, (2003) Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 91: 891-894.
29. Giannoulis MG, Sonksen PH, Umpleby M, Breen L, Pentecost C, et al. (2006) The effects of growth hormone and/or testosterone in healthy elderly men: a randomized controlled trial. J Clin Endocrinol Metab 91: 477-484 Epub 2005 Dec 2006.
30. Toshinai K, Mondal MS, Shimbara T, Yamaguchi H, Date Y, et al. (2007) Ghrelin stimulates growth hormone secretion and food intake in aged rats. Mech Ageing Dev 128: 182-186 Epub 2006 Nov 2015.
31. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, et al. (2001) Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50: 227-232.
32. Barazzoni R, Bosutti A, Stebel M, Cattin MR, Roder E, et al. (2005) Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab 288: E228-235 Epub 2004 Aug 2024.